Don’t miss – Page 14 – Endpoints News

SUBSCRIBE

The top 10 pipeline blowups, setbacks and snafus for H1 2019

4 months ago

Vertex's Reshma Kewalramani takes CEO post as longtime vet Jeff Leiden moves to new role

4 months ago

Bristol-Myers does it again, disappointing investors with a surprise Opdivo PhIII failure as chemo combo flops

4 months ago

GSK culls more respiratory drugs out of PhII as focus shifts to cancer

4 months ago

Celgene restructures a big Jounce pact, zeroing in on new I/O pathway with $530M deal — and bumping ICOS

4 months ago

Stay tuned: Biogen’s numbers are great — it’s their worrisome future that leaves analysts skittish

4 months ago

3 years after the FDA forced Chiasma back into PhIII, they’re back with positive data — but now they have a rival

4 months ago

Acadia is making the best of it, but their latest PhIII Nuplazid study is a bust

4 months ago

Breaking the death spiral: Hal Barron talks about transforming the moribund R&D culture at GSK in a critical year for the late-stage pipeline

4 months ago

Celgene racks up third Otezla approval, heating up talks about who Bristol-Myers will sell to

4 months ago

In another disappointment for investors, FDA slaps down Biohaven’s revised version of an old ALS drug

4 months ago

On a hot streak, Novartis execs run the odds on their two most important PhIII readouts. Which is 0.01% more likely to succeed?

4 months ago

Medicxi is rolling out its biggest fund ever to back Europe's top 'scientists with strange ideas'

4 months ago

After a decade, ViiV CSO John Pottage says it's time to step down — and he's handing the job to longtime colleague Kim Smith

4 months ago

On a global romp, Boehringer BD team picks up its third R&D alliance for July — this time focused on IPF with $50M upfront

4 months ago

Backed by some of the biggest names in biotech, Norbert Bischofberger gets his megaround for platform tech out of MIT

4 months ago

With looming ‘apocalypse of drug resistance,’ Merck’s combination antibiotic scores FDA approval on two fronts

4 months ago

The $1.1M goodbye: Gilead CSO John McHutchison is out as Daniel O’Day shakes up the senior team

4 months ago

Going inside cells, Sung Joo Lee has sketched some big goals for his small — but global — team of drug hunters

4 months ago

Astellas buys into Frequency's regenerative med strategy with a $625M alliance on hearing loss

4 months ago

Part club, part guide, part landlord: Arie Belldegrun is blueprinting a string of bespoke biotech complexes in global boomtowns — starting with Boston

4 months ago

Takeda's translational cell therapy group revs up for a race to the clinic with off-the-shelf CAR-T

4 months ago

Boehringer buys Swiss biotech in its latest M&A deal, going the next-gen cancer vaccine route

4 months ago

AbbVie beefs up the oncology pipeline, bagging an upstart STING player with its own unique approach

4 months ago

First page Previous page 11 12 131415 16 17 Next page Last page